Education
About Us
Working with TipRanks
Follow Us
Daily Stock Ratings & Price Targets
Analyst Performance
Any
Analyst Rating
Any
Upside / Downside
Any
Action
Any
Market Cap
Any
Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
|---|---|---|---|---|---|---|---|---|---|
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €5.6 | ― | 13.80% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €75 | ― | 5.50% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €67→€61 | ― | 3.40% | Reiterated | ||||
 | Arkema | SELL €68.5→€65 | ― | -2.50% | Reiterated | Arkema SA (AKE:FP) (ARKAF) PT Lowered to EUR65 at JPMorganJPMorgan analyst Chetan Udeshi lowered the price target on Arkema SA (AKE:FP) (OTC: ARKAF) to EUR65.00 (from EUR68.50) while maintaining a Underweight rating. | |||
| UBISOFT Entertainment | HOLD €13→€12 | ― | -26.10% | Reiterated | Ubisoft Entertainment SA (UBI:FP) (UBSFY) PT Lowered to EUR12 at Deutsche BankDeutsche Bank analyst George Brown lowered the price target on Ubisoft Entertainment SA (UBI:FP) (OTC: UBSFY) to EUR12.00 (from EUR13.00) while maintaining a Hold rating. | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €4.5→€4 | ― | 1.20% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €1.8 | ― | 10.40% | Initiated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €65 | ― | 4.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €18→€19 | ― | 14.00% | Reiterated | ||||
| Teleperformance | BUY €190 | ― | -4.40% | Reiterated | Berenberg Bank Sticks to Its Buy Rating for Teleperformance (0J6X) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL €26.4 | ― | 10.30% | Reiterated | ||||
 | Hermes International | BUY €2,600 | ― | -5.50% | Initiated | Hermes initiated with an Outperform at RBC Capital | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €95→€93 | ― | 12.90% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €183 | ― | 20.00% | Reiterated | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €239→€235 | ― | 4.50% | Downgraded | ||||
 | Pernod Ricard | HOLD €103→€98 | ― | -1.10% | Reiterated | Pernod Ricard price target lowered to EUR 98 from EUR 103 at Morgan Stanley | |||
 | Robertet | BUY €1,090 | ― | -2.00% | Initiated | Robertet (0NZN) Receives a New Rating from Berenberg Bank | |||
| MaaT Pharma | BUY €22 | ― | -19.30% | Reiterated | Promising ALS Trial Results Bolster Buy Rating for MaaT Pharma Amidst Strategic Oncology Focus | |||
 | Sanofi | BUY €114→€124 | ― | -1.20% | Reiterated | Analysts Are Bullish on These Healthcare Stocks: Sanofi (SNYNF), Healthequity (HQY) | |||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD €37 | ― | 4.10% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €85 | ― | 2.60% | Reiterated | ||||
| MaaT Pharma | BUY €15.5 | ― | -12.60% | Reiterated | Kepler Capital Remains a Buy on MaaT Pharma (MAAT) | |||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €38 | ― | 18.00% | Reiterated | ||||
 xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €55.3 | ― | 1.10% | Upgraded | ||||
| xxxxxxxxxxxxxxxxxx | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY €3.2→€3.7 | ― | 9.80% | Reiterated |
Rows:
